Related by context. All words. (Click for frequent words.) 74 log# copies mL 69 HCV RNA 68 log# IU mL 67 copies mL 67 -#.# log# 67 log# reduction 66 IU mL 66 mcg mL 66 mg TID 66 lumbar spine BMD 65 plasma HCV RNA 65 HIV RNA 65 placebo p 65 mg kg dose 65 mcg kg 64 mg QD 64 μg mL 64 serum HBV DNA 64 HBeAg seroconversion 64 IU ml 64 statistically significant p 63 HBV DNA 63 mg qd 63 ug kg 63 lopinavir r arm 63 4mg/kg 63 achieved ACR# 63 complete cytogenetic 63 antibody titers 62 Cmax 62 -#.# mg dL [002] 62 complete cytogenetic response 62 mg kg 62 undetectable HCV RNA 62 -#.# log# copies mL 62 uM 62 #mg/kg [002] 62 μmol L 62 copies ml 62 mg BID 62 plus methotrexate 62 ACR# response 61 peginterferon alfa 2a 61 3mg/kg 61 undetectable virus HCV 61 ug mL 61 detectable HCV RNA 61 cEVR 61 sUA 61 lopinavir r 61 mcg BID 61 statistical significance p 61 QTcF 61 mg/m2/day 61 HBV DNA levels 61 #mg BID [003] 61 mcg albinterferon alfa 2b 61 8mg/kg 61 ng dL 61 PASI scores 61 sustained virologic response 61 PREZISTA ritonavir 61 viral load 60 MADRS score 60 #.#/#.# mmHg [001] 60 alanine aminotransferase 60 mEq L 60 placebo p = 60 HBeAg negative patients 60 seroprotection 60 μg dose 60 statistically significant p = 60 mg ustekinumab 60 piperacillin tazobactam 60 REYATAZ r arm 60 mmol l 60 #mg/m# [001] 60 baseline A1C 60 CCyR 60 HI titers 60 ug ml 60 g dL 60 Median PFS 60 baseline HbA1c 60 μg ml 60 microg 60 aspartate aminotransferase 59 hemagglutination inhibition 59 CIMZIA TM 59 annualized relapse 59 virologic response 59 pg ml 59 μg kg 59 biochemical relapse 59 pg mL 59 Peg IFN 59 P = .# 59 Crohn Disease Activity 59 viremia 59 amprenavir 59 mg RDEA# 59 partial remissions 59 SVR# 59 peginterferon alfa 2b 59 PSA nadir 59 achieved statistical significance 59 mg/m2 59 mg m² 59 mcg Albuferon 59 mIU ml 59 Lupuzor ™ 59 creatinine ratio 59 oral allopurinol 59 Engerix B 59 virologic 59 #mg BID [001] 59 microgram kg 59 undetectable viral load 59 nM 59 mCi kg 59 undetectable HBV DNA 59 MIC# [001] 59 sUA levels 59 plus prednisone prednisolone 59 #mg QD [002] 59 LPV r 59 Q2W 59 recurrent genital herpes 59 atazanavir ritonavir 59 interferon alfa 2a 58 alanine aminotransferase ALT 58 neutrophil counts 58 oxycodone CR 58 TMC# r 58 pyrazinamide 58 seroconversion 58 ng mL 58 ng dl 58 DAS# [002] 58 mcg dose 58 nmol liter 58 CDAI score 58 CSBMs 58 mIU mL 58 #mg/day [001] 58 mcg QD 58 telaprevir dosed 58 clodronate 58 cells uL 58 saline placebo 58 sustained virological response 58 intramuscular dose 58 mean baseline HbA1c 58 rapid virologic response 58 ritonavir boosted 58 #.#mg/dL 58 median PFS 58 % CI #.#-#.# [003] 58 viral titers 58 MBq 58 mL/min/#.# m2 58 MCyR 58 dosing cohorts 58 nadolol 58 serum urate 58 micrograms mL 58 HBeAg positive patients 58 ug dose 58 Pegasys ® 58 serum phosphorus 58 #.#/#.# mm Hg [003] 58 BPH Symptom Score 58 seropositive patients 58 mg dose 58 achieved sustained virologic 58 DAS# CRP 58 progression TTP 58 mcg doses 58 pmol L 58 prednisone prednisolone plus 58 placebo dexamethasone 57 cytogenetic response 57 evaluable 57 achieved undetectable HCV 57 mCi m 2 57 comparator arm 57 lymphocytosis 57 timepoint 57 experienced virologic failure 57 IFN alpha 57 definite stent thrombosis 57 nanomolar 57 mean baseline A1C 57 posaconazole 57 #ug [001] 57 dapagliflozin plus 57 #μg [002] 57 cells μL 57 #mg/day [002] 57 titers 57 antibody titer 57 IFN α 57 virologic failure 57 p = #.# [002] 57 μg doses 57 clinically meaningful improvement 57 serum HCV RNA 57 pegIFN 57 NNRTI resistance 57 adefovir 57 HBeAg positive 57 plasma concentrations 57 HCV replicon 57 μg L 57 mg Lucentis 57 abacavir lamivudine 57 binary restenosis 57 mg kg hr 57 lispro 57 HBeAg 57 certolizumab 57 doxorubicin cyclophosphamide 57 Psoriasis Area 57 ALVESCO 57 inhibitory concentration 57 p = 57 serum antibody 57 pegylated interferon alpha 57 IgG antibody 57 relapsed MM 57 ± SD 57 intramuscularly 57 peripheral blood mononuclear 57 evaluable subjects 57 budesonide pMDI 57 receiving ISENTRESS 57 % Confidence Interval 56 REYATAZ r 56 FluCAM 56 CR nPR 56 μg 56 receiving golimumab 56 imipenem 56 octreotide LAR 56 q8h 56 response CCyR 56 hours postdose 56 REMICADE monotherapy 56 ALT normalization 56 plus MTX 56 FEV1 56 fasting plasma glucose FPG 56 ertapenem 56 ribavirin RBV 56 CI -#.# 56 indinavir 56 severe neutropenia 56 FOLFOX6 56 RECIST criteria 56 CsA 56 steroid dexamethasone 56 #mg q8h 56 scores TNSS 56 neutrophil count 56 PEG IFN 56 gastric pH 56 evaluable patients 56 pegylated interferon alfa 2a 56 undetectable hepatitis C 56 Folfox 56 HAQ DI 56 Pegasys plus Copegus 56 serologically active patients 56 plus dexamethasone 56 p = #.# [004] 56 mg q#h 56 fosamprenavir 56 receiving VICTRELIS 56 plus OBT 56 low dose cytarabine 56 p = NS 56 neutralizing antibody 56 cyclophosphamide methotrexate 56 ACR# responses 56 intravenous bolus 56 AUA Symptom Score 56 plus ribavirin 56 CK # plasma concentrations 56 chlorambucil 56 administered subcutaneously 56 q#h 56 aspartate aminotransferase AST 56 spontaneous bowel movements 56 #μg [001] 56 Index CDAI 56 mcg linaclotide 56 pegylated interferon alfa 56 PREZISTA r arm 56 -#.# mg dL [001] 56 transaminase elevations 56 seropositivity 56 EDSS score 56 microbiologically evaluable 56 Acetate Rectal Suppositories 56 mmol L 56 Solid Tumors criteria 55 ascending dose 55 Response Evaluation Criteria 55 ABC/3TC 55 IPSS 55 mL sec 55 TDF FTC 55 nucleoside naive 55 infliximab monotherapy 55 mmHg p = 55 titer 55 ng ml 55 lactate dehydrogenase LDH 55 #mg/m# [002] 55 Expanded Disability Status 55 serum phosphate 55 Tumor shrinkage 55 achieved sustained virological 55 cGy 55 mg q8h 55 CR CRu 55 viral kinetics 55 pegylated interferon alfa 2b 55 achieved PASI 55 Virologic 55 serum potassium 55 statistically significant reduction 55 SELENA SLEDAI score 55 HbA1c 55 mg eq 55 leukocyte count 55 aminotransferase elevations greater 55 morphometric vertebral fractures 55 daily Infergen 55 retinal thickness 55 RGT arm 55 ropivacaine 55 Apidra ® 55 mg kg Hematide 55 p = .# [002] 55 lopinavir 55 mg BID dose 55 tipranavir ritonavir 55 DAS# remission 55 mg p = 55 seroconverted 55 serum urate levels 55 Median progression 55 tipranavir r 55 PegIFN RBV 55 postdose 55 docetaxel chemotherapy 55 linaclotide treated 55 seroprotective 55 LEXIVA r 55 mL/min/#.# m 2 55 mg tid 55 mcg kg min 55 baseline Hb 55 plasma leptin 55 pfu 55 specific antigen PSA 55 pCR 55 mg m 55 Hb A1C 55 lymphocyte count 55 EpCAM expression 55 μSv 55 daunorubicin 55 virologic response EVR 54 peginterferon alfa 2a #KD 54 naïve HCV 54 mg d 54 LANTUS R 54 adefovir treated 54 5-FU/LV 54 splenectomized patients 54 X ULN 54 mg dL 54 discontinuations due 54 concentration Cmax 54 cisplatin gemcitabine 54 median CD4 54 achieved CCyR 54 mg Androxal 54 #.#mg/kg [002] 54 Median survival 54 baseline LDH 54 dexamethasone Decadron 54 dacarbazine 54 PEG Intron 54 interferon alfa 54 SUVmax 54 dosed orally 54 peg IFN 54 #Gy 54 intravenous REOLYSIN 54 baseline neutrophil counts 54 FOLFIRI 54 transaminase 54 alfa 2a 54 HCV viral 54 Hazard Ratio HR 54 serum aminotransferase levels 54 placebo 54 Platelet counts 54 active comparator 54 IRLS score 54 serum concentrations 54 #.#-#.# [011] 54 PEG Interferon alfa 54 BARACLUDE ® 54 cfu 54 dose cohorts 54 azathioprine monotherapy 54 mg simvastatin 54 NIHSS 54 mitoxantrone plus 54 #mg QD [001] 54 dose cohort 54 mg orally 54 nmol L 54 mcg kg REBETOL 54 viral titer 54 plus GP IIb 54 HCV genotypes 54 pegylated liposomal doxorubicin 54 genotype 1b 54 #.#ng/ml 54 IIIa inhibitors 54 desvenlafaxine succinate 54 LVEF 54 RNA copies mL 54 coinfected 54 Sustained virologic response 54 Aptivus ® 54 ritonavir boosted atazanavir 54 μM 54 TEAEs 54 ≥ 54 pooled comparator 54 degarelix 54 receiving INTRON 54 PROCTOCORT ® Suppository Hydrocortisone 54 rFSH 54 % CI #.#-#.# [007] 54 serum ALT 54 abnormal p# biomarker 54 unfractionated heparin UFH 54 flutamide 54 Index CDAI score 54 mg subcutaneously 54 kg -1 54 TPV r 54 estramustine 54 microliter 54 mU liter 54 erythrocyte sedimentation rate 54 virological response 54 remission CR 54 Viral load 54 febrile neutropenia 54 cisplatin vinorelbine 54 belimumab 54 ml kg 54 fluorouracil leucovorin 54 CDAI 54 mg/# h 54 MADRS 54 avosentan 54 Rapid Virological Response 54 FOLFOX4 alone 54 chronic HCV genotype 54 COMBIVIR 54 invasive carcinomas 54 sd = 54 inflammatory lesions 54 nitazoxanide 54 alfa 2b 54 amoxicillin clavulanate 54 -#.# ± [002] 54 mCi 54 gemcitabine carboplatin 54 Partial Responses 54 serum testosterone 54 specific alkaline phosphatase 54 creatinine clearance 54 CD4 + cell 54 locoregional disease 54 plasma uric acid 54 NPH insulin 54 % CI #.#-#.# [006] 54 lactate dehydrogenase 54 peg interferon 54 rizatriptan 54 ceftazidime 54 demonstrated statistically significant 54 Ishak fibrosis score 54 Hazard Ratio 54 atheroma volume 54 mg/m2 dose 54 n = 54 FFNS 53 IIIa inhibitor 53 doripenem 53 Pred Forte 53 fluorouracil 53 pegylated interferon 53 HPV-#/# 53 anemia hemoglobin 53 Knodell necroinflammatory score 53 median survivals 53 tipranavir 53 min -1 53 Peginterferon Alfa 2a 53 fluticasone salmeterol 53 subcutaneously administered 53 ADCS ADL 53 sham injections 53 Viread Emtriva Sustiva 53 mL kg 53 ALT elevation 53 ribavirin therapy 53 â ‰ ¥ 53 Scale EDSS score 53 TAXUS p value 53 FOLFOX 53 Pegylated Interferon 53 placebo fluoxetine 53 posttreatment 53 #mg BID [002] 53 Secondary endpoints include 53 glycated hemoglobin levels 53 mg Proellex 53 intratumoral 53 statin monotherapy 53 Actilon 53 cytogenetic responses 53 ± SEM 53 ULORIC 53 g mL 53 serum IGF 53 APTIVUS r 53 oxycodone IR 53 urinary albumin 53 azacytidine 53 baseline FEV 53 VELCADE melphalan 53 HCV genotype 53 Omacetaxine 53 subcutaneously 53 HDRS 53 nicardipine 53 patients evaluable 53 x ULN 53 recurrent VTE 53 DLTs 53 FluCAM arm 53 urinary N telopeptide 53 salmeterol fluticasone propionate 53 adriamycin 53 oblimersen 53 vancomycin 53 tPSA 53 EUFLEXXA R 53 free survival PFS 53 subcutaneous doses 53 azacitidine 53 AZT zidovudine Retrovir 53 placebo PBO 53 refractory NSCLC 53 leukopenia 53 p ≤ 53 FOLFOX4 53 g dl 53 transaminases 53 virologic breakthrough 53 eGFR 53 ADAS cog 53 achieve sustained virological 53 intraperitoneal injection 53 tirofiban 53 HBsAg 53 #.#g/day 53 leuprorelin 53 insulin detemir 53 genotypic resistance 53 IFN alfa 53 elevated transaminases 53 tapentadol ER 53 highly emetogenic 53 Pegasys peginterferon alfa 2a 53 ceftriaxone 53 viral loads 53 timepoints 53 generalized edema 53 serum prostate 53 Serum creatinine 53 SCIg 53 pT3 53 resected pancreatic cancer 53 evaluating tivozanib 53 dsDNA 53 Montgomery Asberg Depression 53 PegIFN 53 mg/# hours 53 mmHg 53 calculated creatinine clearance 53 Solid Tumors RECIST 53 plus aztreonam 53 splenectomized 53 PBMCs 53 null responders 53 S/GSK# 53 fractional shortening 53 CRp 53 Scale EDSS 53 tolterodine ER 53 5FU 53 carboplatin paclitaxel 53 mcL 53 mg kg cohorts 53 highest tertile 53 mmHg diastolic 53 receiving APTIVUS r 53 μg liter 53 EGFR TKI 53 serum clusterin levels 53 #mg/dL [002] 53 interleukin IL -6 53 NOAEL 53 TNFalpha 53 mg dosed twice 53 ACR Pedi 53 methotrexate monotherapy 53 telaprevir pegylated interferon 53 #mg dose [002] 53 CK MB 52 FOLFIRI alone 52 platelet reactivity 52 hemagglutination inhibition HAI 52 anthracycline taxane 52 HOMA IR 52 incontinence episodes 52 TIMP 1 52 paraprotein 52 lamivudine monotherapy 52 PREZISTA r 52 systolic diastolic blood 52 #mg #mg #mg [003] 52 apolipoprotein B 52 mg subcutaneous 52 #mg/kg [001] 52 Lantus ® 52 tumor shrinkage 52 Partial Response 52 micromoles 52 PaO 2 52 CIMZIA ™ 52 trough FEV1 52 R# #mg BID 52 hemoglobin Hb 52 ara C 52 mmHg p 52 gout flare 52 NovoLog ® Mix 52 rifabutin 52 oral rivaroxaban 52 corticosteroid dose 52 microbiological eradication 52 cells/mm3 52 glycated hemoglobin HbA1c 52 glulisine 52 linezolid 52 μg dL 52 nmol 52 baminercept 52 serum creatinine levels 52 XIENCE V PROMUS Stent 52 NIH CPSI 52 postintervention 52 QbG# 52 ml min 52 tumor regression 52 nevirapine Viramune 52 CSBM 52 titres 52 cells mcL 52 inhibin B 52 primary efficacy endpoint 52 Kinoid 52 treatment naïve genotype 52 goserelin 52 IgM 52 adjunctive placebo 52 viral suppression 52 valopicitabine 52 HbA 1c 52 racemic albuterol 52 pg g 52 doxorubicin docetaxel 52 mg/m2 IV 52 tenofovir emtricitabine 52 CHOP chemotherapy 52 #mg doses [002] 52 APOPTONE 52 microlitre 52 Navelbine 52 Tipranavir 52 K#N 52 ipsilateral stroke 52 viraemia 52 elevated ALT 52 oral vancomycin 52 mL 52 Zometa hazard 52 moderate renal impairment 52 HCV genotype 1 52 SGOT 52 Lucentis monotherapy 52 PASI score 52 seronegative 52 Free Survival PFS 52 biologic DMARD 52 zoledronate 52 serum cortisol 52 Severity Index PASI 52 parasitaemia 52 Flu Cy 52 darunavir ritonavir 52 tumor regressions 52 insulin glargine 52 undetectable viral 52 ACR# ACR# 52 Baseline characteristics 52 mg kg belimumab 52 Secondary endpoints included 52 Telbivudine 52 caspofungin 52 FTC TDF 52 incidence ≥ 52 interferon alfa 2b 52 SGPT 52 T2 lesions 52 Hycamtin ® 52 dosing cohort 52 CFU g 52 YMRS 52 mitoxantrone 52 mmol kg 52 Scale cognitive subscale 52 kilogram mg kg 52 interquartile range 52 peginterferon alfa 2a Pegasys 52 -#.# mmol L 52 HLA DR2 52 dose cytarabine 52 Omacetaxine mepesuccinate 52 P ≤ 52 ibandronate 52 decitabine 52 lamivudine 52 aminotransferases 52 #.#mmol L [001] 52 serologically active SLE 52 concomitant antibiotics 52 IOP lowering 52 subcutaneous enoxaparin 52 statistically significant improvement 52 UGT#A# * 52 efavirenz EFV 52 hepatitis C genotype 52 HCV Genotype 52 UACR 52 dose dexamethasone 52 #mg dose [001] 52 virologic suppression 52 autoantibody positive 52 nodular partial response 52 ACR# [002] 52 oral levofloxacin 52 iPTH 52 Fludara 52 LAB GHRH 52 serum phosphorous 52 irbesartan 52 serum IgG 52 troponin T 52 subcutaneous dose 52 endoscopic remission 52 dalteparin 52 quetiapine XR 52 ethambutol 52 FLT3 ITD 52 β blocker 52 laboratory abnormalities 52 mol L 52 Mg Uk 52 locoregional recurrence 52 microgram mcg 52 PRADAXA #mg 52 myeloperoxidase 52 REYATAZ R 52 endometrial thickness 52 hemoglobin concentration 52 lanthanum carbonate 52 standard chemotherapy regimen 52 SCr 52 baseline CD4 + 52 peginterferon 52 #ug [002] 51 tacrolimus ointment 51 telbivudine 51 IELT 51 Treatment Naive Patients 51 micromolar 51 HAM D# scores 51 Decitabine 51 ALT flares 51 LS BMD 51 dose proportionality 51 p = #.# [003] 51 apnea hypopnea index 51 PEGylated anti 51 titrated glipizide 51 antiviral activity 51 IV bolus 51 antiviral efficacy 51 ± 51 microliters 51 mutated KRAS 51 mcg dL 51 SBMs 51 peak plasma concentrations 51 antithymocyte globulin 51 confidence interval CI 51 eosinophil count 51 bolus injection 51 comparator PI r 51 mU L 51 bicalutamide 51 mapatumumab 51 PSADT 51 antiretroviral naïve 51 μL 51 alpha 2a 51 ascending doses 51 HBeAg negative 51 serum creatinine 51 thyroglobulin 51 KRAS mutations occur 51 Cream USP 1 51 FOLPI regimen 51 mu g 51 Ki# 51 TLUS 51 anti HBs 51 hypophosphatemia 51 pegylated alpha interferon 51 mg dl 51 glycosylated hemoglobin HbA1c 51 zonisamide SR 51 imatinib therapy 51 RECIST Response Evaluation Criteria 51 mg 51 Pharmacokinetics PK 51 replicon 51 alkaline phosphatase 51 virologic responses 51 Copegus ribavirin 51 HbA 1c levels 51 IgG antibodies 51 idraparinux 51 plasma glucose 51 ‰ ¥ 51 adalimumab 51 activated partial thromboplastin 51 + PH# 51 reinfarction 51 mITT population 51 sweat chloride 51 liver histology 51 underwent surgical resection 51 receiving PEGINTRON 51 SBM frequency 51 neurologic progression 51 plus prednisone 51 hepatic enzymes 51 achieve sustained virologic 51 -#.# ± [001] 51 insulin degludec 51 mmol 51 TURBT 51 ACTEMRA TM 51 mg XP# 51 mm Hg 51 curve AUC 51 Sustained Virological Response 51 Virologic failure 51 Xalatan R 51 dizziness nausea diarrhea 51 mL min 51 Primary Endpoint 51 HUMIRA achieved PASI 51 weekly intravenous infusions 51 plus medroxyprogesterone acetate 51 HbA1c levels 51 #ng/ml 51 TMC# [001] 51 baseline PASI 51 null responder HCV 51 PEG Intron ® 51 mcg 51 pretreatment baseline 51 CLL SLL 51 interferon alpha 51 serum leptin 51 Rating Scale MADRS 51 peginterferon alpha 2a 51 tumor progression TTP 51 glomerular filtration rate 51 potent CYP#A# inhibitors 51 microgram doses 51 hour bronchodilation 51 darunavir r 51 subcutaneous injections 51 neutropenia dehydration dyspnea 51 #mg ritonavir 51 Non inferiority 51 antiretroviral naive 51 docetaxel 51 metformin IR 51 valsartan 51 ® emtricitabine 51 antiandrogen 51 uL 51 Sustained Virologic Response 51 triacylglycerol 51 3TC lamivudine Epivir 51 AUA BPH Symptom Score 51 milatuzumab 51 treatment naļve 51 zolmitriptan 51 fraction LVEF 51 TIMP 51 hematologic toxicity 51 primary endpoint 51 PANSS 51 mmHg systolic 51 HER2 expression 51 estimated glomerular filtration 51 FDA defined valvulopathy 51 lamivudine refractory patients 51 Gy fractions 51 trastuzumab Herceptin ® 51 5mg/kg 51 Durezol 51 virologic failures 51 #.#mL 51 IGFBP 51 nadroparin 51 NRTI 51 PCWP 51 Viread Emtriva 51 pulmonary exacerbations 51 proteinuria 51 hemoglobin A1c HbA1c 51 aPTT 51 lymphocyte counts 51 undetectable viral loads 51 mmol L. 51 Score DAS# 51 BCVA 51 GnRH agonist 51 intracranial hemorrhage ICH 51 CANCIDAS 51 lopinavir ritonavir Kaletra 51 CIMZIA TM certolizumab pegol 51 serum PTH 51 postop 51 sievert 51 PEGPH# 51 mm3 51 treatment naive genotype 51 Primary endpoints 51 bupivacaine 51 gemcitabine cisplatin 51 CIN3 51 Cethromycin 51 hip BMD 51 T#I [002] 51 busulfan 51 Secondary efficacy endpoints 51 lymphoid blast